

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 28 April 2021

Situation Report No. 255 - Kingdom of Bahrain
29th of April, 2021






	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	148,999,876	3,140,115	9,017,147	180,906
New	2,223,877 in 3 days	35,904 in 3 days	144,685 in 3 days	2,915 in 3 days

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
	Total	174,695	163,937	632	10,126	104	4,060,011	681,686
New	3,325 in 3 days	3,848 in 3 days	8 in 3 days	-	-	46,655 in 3 days	-	-

HIGHLIGHTS

- The Mortality were: 3 Bahraini citizens (3 male (61, 67 and 87 years old) and 3 Female (56, 58 and 79 years old)) and 6 expatriates (1 male (33 years old) and 1 Female (41 years old)).
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 25 April 2021 for the first dose (681,686) and for the second dose (534,673).
- National Medical Taskforce for Combating the Coronavirus (COVID-19) highlighted the success of the Kingdom's National Vaccination Campaign, backed with reduction of transmission rates by an average of 93%.
- MOH Undersecretary indicated that during the months of March and April, only 2% of existing cases are travel related, indicating that travelers procedures (to take PCR tests upon arrival, as well as on the 5th and 10th day of stay) are effective.
- MOH Undersecretary called to register for the first available COVID-19 vaccine appointment, stressing that all vaccines were rigorously approved by the National Health Regulatory Authority for safety and efficacy.
- MOH Undersecretary revealed that current COVID-19 recovery rate is at 93.7% with about 0.36% case fatality rate (CFR); while occupancy at isolation centers stands at 48% with 3,002 beds occupied out of 3,249 available; and 7,283 asymptomatic cases are under optional home self-isolation.
- BDF Hospital indicated that despite the presence of mutated strains of the virus, vaccines have provided immunity and protected individuals by relieving symptoms.
- BDF Hospital added that the National Vaccination Campaign has reduced the transmission of infection among all age groups by an average of 93%.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of dengue surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen testing in the diagnosis of SARS-CoV-2 infection using rapid immunoassay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work; see link below.
- WHO-ICMARA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guideline: Theapeutics and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, Therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: COVID-19 Virtual Press conference transcript; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.
- WHO: Guideline Development Group Living Guidelines for COVID-19; see link below.
- WHO statement on AstraZeneca COVID-19 vaccine safety signals; see link below.
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work?; see link below.
- Update 55 - WHO COVID-19 guidelines development process; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.
- WHO: Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine; see link below.
- WHO: COVAX reaches over 100 economies, 42 days after first international delivery; see link below.
- WHO-backed global youth mobilization funds young people's ideas to combat impact of COVID-19 pandemic; see link below.
- COVID-19 vaccines: Knowledge gaps and research priorities - WHO ad hoc consultation; see link below.
- WHO: One-year of Access to COVID-19 Tools Accelerator; see link below.



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/emergencies/situation-reports/20200817-weekly-epi-update-1.pdf?fbclid=IwAR6B9a79_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news/item/21-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of dengue surveys: <https://www.who.int/publications/m/item/918-92-4-21-254-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/2v8v0Df>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: <https://www.who.int/publications/m/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen testing in the diagnosis of SARS-CoV-2 infection using rapid immunoassay: <https://bit.ly/2Z0W0YF>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2DwW0VQ>
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS: <https://bit.ly/34W9W53>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/31105ZF>
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work: <https://bit.ly/37720W6>
- WHO: Report for eCOVID-19 vaccine: <https://bit.ly/37720W6>
- WHO-ICMARA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3jz9tM4>
- WHO Living Guideline: Theapeutics and COVID-19: <https://www.who.int/publications/m/item/2020-11-10-living-guideline-the-therapeutics-and-covid-19>
- WHO: Interim guidance on Diagnostics, Therapeutics, vaccine readiness, and other health products for COVID-19: <https://www.who.int/publications/m/item/2020-11-10-interim-guidance-on-diagnostics-therapeutics-vaccine-readiness-and-other-health-products-for-covid-19>
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/m/item/2020-11-10-evidence-to-recommendations-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: <https://www.who.int/publications/m/item/2020-11-10-health-workforce-policy-and-management-in-the-context-of-the-covid-19-pandemic-response>
- WHO: COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/m/item/2020-11-10-covid-19-vaccine-introduction-and-deployment-costing-tool>
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: <https://www.who.int/publications/m/item/2020-11-10-considerations-for-implementing-a-risk-based-approach-to-international-travel-in-the-context-of-covid-19>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: <https://www.who.int/publications/m/item/2020-11-10-risk-assessment-tool-to-inform-mitigation-measures-for-international-travel-in-the-context-of-covid-19>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: <https://www.who.int/publications/m/item/2020-11-10-rational-use-of-personal-protective-equipment-for-coronavirus-disease-covid-19-and-considerations-during-severe-shortages>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/21-09-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/item/21-09-2020-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>
- WHO: Guideline Development Group Living Guidelines for COVID-19: <https://www.who.int/publications/m/item/2020-11-10-guideline-development-group-living-guidelines-for-covid-19>
- WHO statement on AstraZeneca COVID-19 vaccine safety signals: <https://www.who.int/news/item/21-09-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals>
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work? <https://www.who.int/publications/m/item/2020-11-10-what-is-the-access-to-covid-19-tools-act-accelerator-how-is-it-structured-and-how-does-it-work>
- Update 55 - WHO COVID-19 guidelines development process: <https://www.who.int/publications/m/item/2020-11-10-update-55-who-covid-19-guidelines-development-process>
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines: <https://www.who.int/publications/m/item/2020-11-10-draft-landscape-and-tracker-of-covid-19-candidate-vaccines>
- WHO: Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine: <https://www.who.int/publications/m/item/2020-11-10-interim-statement-of-the-covid-19-subcommittee-of-the-who-global-advisory-committee-on-vaccine-safety>
- WHO: COVAX reaches over 100 economies, 42 days after first international delivery: <https://www.who.int/news/item/21-09-2020-covax-reaches-over-100-economies-42-days-after-first-international-delivery>
- WHO-backed global youth mobilization funds young people's ideas to combat impact of COVID-19 pandemic: <https://www.who.int/news/item/21-09-2020-who-backed-global-youth-mobilization-funds-young-peoples-ideas-to-combat-impact-of-covid-19-pandemic>
- COVID-19 vaccines: Knowledge gaps and research priorities - WHO ad hoc consultation: <https://www.who.int/publications/m/item/2020-11-10-covid-19-vaccines-knowledge-gaps-and-research-priorities-who-ad-hoc-consultation>
- WHO: One-year of Access to COVID-19 Tools Accelerator: <https://www.who.int/publications/m/item/2020-11-10-one-year-of-access-to-covid-19-tools-accelerator>

IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAIi@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh